Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation

Amir T. Fathi, Traci M. Blonquist, Daniela Hernandez, Philip C. Amrein, Karen K. Ballen, Malgorzata McMasters, David E. Avigan, Robin Joyce, Emma K. Logan, Gabriela Hobbs, Andrew M. Brunner, Christelle Joseph, Ashley M. Perry, Meghan Burke, Tanya Behnan, Julia Foster, Meghan K. Bergeron, Jenna A. Moran, Aura Y. Ramos, Tina T. SomJessica Rae, Kaitlyn M. Fishman, Kristin L. McGregor, Christine Connolly, Donna S. Neuberg, Mark J. Levis

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation'. Together they form a unique fingerprint.

Medicine & Life Sciences